Giving Immune Checkpoint Inhibitors Within 90 Days of Radiation Appears Safe
Rates of adverse events were generally similar between patients who did and did not receive radiation.
Kidney Cancer
Atezolizumab Plus Bevacizumab Does Not Improve OS in Renal Cell Carcinoma
The overall survival results were similar between the treatment arms for the overall cohort and for patients with PD-L1+ disease.
Tumor Size Affects Survival After Cytoreductive Nephrectomy for RCC
There is no universal approach to patient selection for cytoreductive nephrectomy.
Diabetes Not a Major Driver of Oncologic Outcomes in Renal Cell Carcinoma
Researchers have questioned whether diabetes exerts adverse effects on the prognosis of RCC.
Belzutifan Demonstrates Efficacy in VHL-Associated Renal Cell Carcinoma
Belzutifan demonstrated activity against both RCC and non-RCC neoplasms associated with VHL disease.
Can Quality of Life Assessments Predict PFS, OS Across Cancer Types?
Recent studies showed associations between quality of life scores and survival in lung and prostate cancer as well as renal cell carcinoma.
Radiation Therapy for Oligometastatic Renal Cell Carcinoma Promising
Serial radiation therapy could provide an alternative to standard-of-care systemic therapy.
Adverse Radiologic and Pathologic Features Predict Worse Survival Outcomes in Small Renal Masses Following Nephrectomy
Researchers hypothesized that adverse radiologic and pathologic T3 features are predictive of worse outcomes in small renal masses.
Cytoreductive Nephrectomy Plus Active Surveillance Benefits Some With Metastatic Renal Cell Carcinoma
The median cancer-specific survival was 56.5 months.
First-Line Nivolumab Plus Ipilimumab May Offer Greater Cost Efficiency Than Pembrolizumab Plus Axitinib in Advanced Renal Cell Carcinoma
The monthly incremental cost per survivor relative to sunitinib for nivolumab plus ipilimumab decreased over time from $90,035 for 12 months to $18,881 for 48 months.
- Loading...
Loading...
Loading... 
Loading...